ClinicalTrials.Veeva

Menu

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Pfizer logo

Pfizer

Status

Completed

Conditions

Metastatic Renal Cell Carcinoma

Treatments

Drug: Sunitinib

Study type

Observational

Funder types

Industry
Other

Identifiers

NCT04076787
A6181229

Details and patient eligibility

About

This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.

Full description

Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the IMDC database. Patients were classified as favorable, intermediate, or poor prognostic risk group according to IMDC criteria. Overall survival, time to treatment discontinuation, and physician-assessed tumor response were evaluated.

Enrollment

1,769 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed with mRCC
  • Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
  • Age 18 years or over at the time of mRCC diagnosis
  • Actively treated at an IMDC clinical center

Exclusion criteria

  • Initiated first line sunitinib treatment before 2010
  • Had non-clear cell mRCC

Trial design

1,769 participants in 3 patient groups

Favorable IMDC risk group
Description:
The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
Treatment:
Drug: Sunitinib
Intermediate IMDC risk group
Description:
The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
Treatment:
Drug: Sunitinib
Poor IMDC risk group
Description:
The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
Treatment:
Drug: Sunitinib

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems